Provided by Tiger Trade Technology Pte. Ltd.

Lineage

37.75
+0.36000.96%
Post-market: 37.750.00000.00%19:30 EDT
Volume:1.05M
Turnover:39.68M
Market Cap:8.57B
PE:-52.43
High:37.95
Open:37.40
Low:37.09
Close:37.39
52wk High:45.75
52wk Low:31.33
Shares:227.08M
Float Shares:57.19M
Volume Ratio:1.19
T/O Rate:1.84%
Dividend:2.12
Dividend Rate:5.62%
EPS(TTM):-0.7200
EPS(LYR):-0.4300
ROE:-2.04%
ROA:0.75%
PB:1.09
PE(LYR):-87.79

Loading ...

Lineage Inc expected to post a loss of 6 cents a share - Earnings Preview

Reuters
·
May 04

Earning Preview: Lineage this quarter’s revenue is expected to decrease by 1.25%, and institutional views are leaning bullish

Earnings Agent
·
Apr 29

Lineage Cell Therapeutics Initiated at Buy by Canaccord Genuity

Dow Jones
·
Apr 29

Canaccord Genuity Initiates Coverage on Lineage Cell Therapeutics With Buy Rating, $9 PT

MT Newswires Live
·
Apr 28

Lineage Cut to Underweight From Equal-Weight by Barclays

Dow Jones
·
Apr 27

Lineage Inc. : Barclays Cuts to Underweight From Equal-Weight

THOMSON REUTERS
·
Apr 27

Lineage downgraded to Underweight from Equal Weight at Barclays

TIPRANKS
·
Apr 27

Barclays downgrades Lineage, Inc. (LINE) to a Sell

TIPRANKS
·
Apr 27

Provaris advances hydrogen and CO2 shipping technologies with Yinson and “K” LINE

TIPRANKS
·
Apr 24

Press Release: VALUE LINE, INC. DIVIDEND HAS JUST BEEN RAISED FROM $1.30 TO $1.40 (ANNUALIZED) -- ITS 12TH CONSECUTIVE INCREASE

Dow Jones
·
Apr 18

Lineage, Inc. (LINE) Receives a Hold from Wells Fargo

TIPRANKS
·
Apr 14

Lineage CTO Thattai plans to retire in 2027; IT leadership shifts to Chris Johnson

Reuters
·
Apr 09

Lineage, Inc. Announces Chief Information Officer and Chief Transformation Officer Retirement and Transition Plan

THOMSON REUTERS
·
Apr 09

Lineage Cell Therapeutics management to meet with Craig-Hallum

TIPRANKS
·
Apr 09

Lineage Is Maintained at In-Line by Evercore ISI Group

Dow Jones
·
Apr 07

Lineage to report first-quarter results, host conference call

Reuters
·
Apr 03

Lineage Is Maintained at Neutral by Piper Sandler

Dow Jones
·
Apr 02

Lineage Cell Therapeutics Is Maintained at Buy by B. Riley Securities

Dow Jones
·
Mar 25

B. Riley Raises Price Target on Lineage Cell Therapeutics to $4 From $3, Keeps Buy Rating

MT Newswires Live
·
Mar 25

Lineage Cell launches cell therapy program in corneal endothelial disease

TIPRANKS
·
Mar 24